Hudson Value Partners LLC Has $6.36 Million Position in Johnson & Johnson (NYSE:JNJ)

Hudson Value Partners LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 7.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,324 shares of the company’s stock after selling 3,079 shares during the period. Johnson & Johnson accounts for about 2.4% of Hudson Value Partners LLC’s portfolio, making the stock its 10th biggest holding. Hudson Value Partners LLC’s holdings in Johnson & Johnson were worth $6,356,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. MRP Capital Investments LLC increased its stake in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co increased its position in Johnson & Johnson by 4.9% in the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after acquiring an additional 65 shares during the period. Denali Advisors LLC increased its position in Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after acquiring an additional 67 shares during the period. Sage Mountain Advisors LLC increased its position in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after acquiring an additional 67 shares during the period. Finally, Sovereign Financial Group Inc. increased its position in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after acquiring an additional 69 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $151.33 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market cap of $364.11 billion, a P/E ratio of 16.83, a P/E/G ratio of 2.27 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The stock’s 50 day simple moving average is $154.01 and its 200 day simple moving average is $153.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s payout ratio is currently 57.84%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Raymond James Financial dropped their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Barclays dropped their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Finally, Bank of America dropped their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Eleven analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.